Last reviewed · How we verify
Corticosteroids for Systemic Use
Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression in immune cells.
Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression in immune cells. Used for Inflammatory and autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis, vasculitis), Severe allergic reactions and anaphylaxis, Adrenal insufficiency.
At a glance
| Generic name | Corticosteroids for Systemic Use |
|---|---|
| Sponsor | University Hospital, Caen |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids are synthetic derivatives of cortisol that act as potent anti-inflammatory and immunosuppressive agents. They bind to intracellular glucocorticoid receptors, translocate to the nucleus, and alter transcription of pro-inflammatory cytokines, adhesion molecules, and other mediators. This results in reduced recruitment and activation of immune cells, decreased vascular permeability, and suppression of both innate and adaptive immune responses.
Approved indications
- Inflammatory and autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis, vasculitis)
- Severe allergic reactions and anaphylaxis
- Adrenal insufficiency
- Chronic obstructive pulmonary disease exacerbations
- Organ transplant rejection prophylaxis
Common side effects
- Hyperglycemia
- Hypertension
- Osteoporosis
- Immunosuppression/increased infection risk
- Insomnia
- Mood changes (anxiety, depression)
- Gastrointestinal upset
- Cushingoid features
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (PHASE3)
- Saphnelo Use in Females of Child-bearing Potential
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) (PHASE3)
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- Steroid Use in Treatment of Allergic Reactions to Food (PHASE4)
- Vitamin D Homeostasis in Sarcoidosis (PHASE4)
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corticosteroids for Systemic Use CI brief — competitive landscape report
- Corticosteroids for Systemic Use updates RSS · CI watch RSS
- University Hospital, Caen portfolio CI